Research ArticlesMedicine

A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory

See allHide authors and affiliations

Science Translational Medicine  05 Nov 2014:
Vol. 6, Issue 261, pp. 261ra153
DOI: 10.1126/scitranslmed.3009185

You are currently viewing the editor's summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution

An Ounce of HCV Prevention

Chronic hepatitis C virus (HCV) infection causes liver inflammation that can lead to diminished liver function or liver failure. Recent approval of antiviral drugs for HCV affords health care providers with treatment options; however, these new therapies are expensive with limited availability, leaving the door open for preventative approaches such as vaccines. Swadling et al. report a first-in-human trial of a prime-boost vaccine strategy for HCV. They prime with a simian adenoviral vector followed by a modified vaccinia Ankara vector encoding HCV proteins, which induces a T cell response similar to that found in HCV control in natural infection. If this strategy can show efficacy in later-stage studies, this approach could be used in a preventative HCV vaccine.

View Full Text